Trials / Completed
CompletedNCT02395133
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 422 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to assess the ability of different Dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with Dupilumab monotherapy compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered. |
| DRUG | Placebo | Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW). |
Timeline
- Start date
- 2015-03-25
- Primary completion
- 2016-07-01
- Completion
- 2016-10-18
- First posted
- 2015-03-20
- Last updated
- 2020-03-11
- Results posted
- 2018-10-17
Source: ClinicalTrials.gov record NCT02395133. Inclusion in this directory is not an endorsement.